Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Inclusion Criteria: * Diagnosis of BCR-ABL positive CML in early chronic phase CML. Except for hydroxyurea, patients must have received no or minimal prior therapy, defined as \<2 weeks (14 days) of prior FDA approved TKI. * ECOG performance of 0-2 * Adequate end organ function, defined as the following: total bilirubin \<1.5x ULN, SGPT \<2.5x ULN, creatinine \<1.5x ULN. * Patients must sign an informed consent indicating they are aware of the investigational nature of this study. Exclusion Criteria: * NYHA cardiac class 3-4 heart disease or previous pleural effusion. * Pregnancy and lactation * Patients with active, uncontrolled psychiatric disorders